NEW YORK, Nov. 10, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN), concerning whether the board has breached its fiduciary duties to shareholders.
On November 9, 2016, an investigation was disclosed concerning the sales practices for Soliris, its flagship and costly drug, used for rare blood disorders. Soliris accounts for the majority of the Company's sales and its third-quarter financials being delayed.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Alexion and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.